Analysts Set OrthoPediatrics Corp. (NASDAQ:KIDS) Price Target at $24.67

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $24.7778.

Several research firms recently commented on KIDS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Tuesday. Truist Financial increased their target price on OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a report on Monday, March 2nd. Canaccord Genuity Group set a $25.00 price target on OrthoPediatrics in a research note on Friday. Needham & Company LLC boosted their price target on OrthoPediatrics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th.

Insider Transactions at OrthoPediatrics

In other news, insider Joseph W. Hauser sold 8,596 shares of OrthoPediatrics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $17.25, for a total value of $148,281.00. Following the sale, the insider directly owned 194,767 shares in the company, valued at $3,359,730.75. This trade represents a 4.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Fred Hite sold 12,993 shares of OrthoPediatrics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $224,129.25. Following the completion of the sale, the chief financial officer owned 277,477 shares in the company, valued at $4,786,478.25. This trade represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 58,171 shares of company stock worth $1,003,450. Corporate insiders own 32.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock worth $246,000 after buying an additional 645 shares in the last quarter. Millennium Management LLC grew its holdings in shares of OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after acquiring an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after acquiring an additional 106,041 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of OrthoPediatrics in the first quarter valued at about $389,000. Finally, American Century Companies Inc. increased its position in shares of OrthoPediatrics by 12.5% in the second quarter. American Century Companies Inc. now owns 34,486 shares of the company’s stock valued at $741,000 after acquiring an additional 3,828 shares during the last quarter. Institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Stock Performance

KIDS stock opened at $16.19 on Thursday. The business’s 50-day moving average price is $16.88 and its two-hundred day moving average price is $17.34. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. The firm has a market cap of $415.92 million, a PE ratio of -9.58 and a beta of 1.16. OrthoPediatrics has a 1-year low of $14.91 and a 1-year high of $23.70.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The company had revenue of $61.61 million during the quarter, compared to the consensus estimate of $61.27 million. As a group, research analysts forecast that OrthoPediatrics will post -1.07 earnings per share for the current year.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.